Clinical outcomes of orbital irradiation combined with or without systemichigh-dose or pulsed corticosteroids for Graves' ophthalmopathy

Citation
K. Tsujino et al., Clinical outcomes of orbital irradiation combined with or without systemichigh-dose or pulsed corticosteroids for Graves' ophthalmopathy, INT J RAD O, 48(3), 2000, pp. 857-864
Citations number
23
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
ISSN journal
03603016 → ACNP
Volume
48
Issue
3
Year of publication
2000
Pages
857 - 864
Database
ISI
SICI code
0360-3016(20001001)48:3<857:COOOIC>2.0.ZU;2-Z
Abstract
Purpose: To evaluate the outcomes of orbital irradiation with or without hi gh-dose or pulsed corticosteroids in patients with Graves' ophthalmopathy ( GO). Methods and Materials: One hundred and twenty-one patients,vith moderate to severe GO who received orbital irradiation from 1987 to 1997 were retrospe ctively analyzed. A total dose of 20 Gy in 10 fractions was delivered to th e bilateral retrobulbar volume. Eighty-six patients were treated in combina tion with high-dose or pulsed corticosteroids and irradiation. Univariate a nd multivariate analyses were performed to assess the prognostic variables. Results: The median follow-up period was 26 months. The overall clinical re sponse was evaluated as excellent in 17 patients (14%), good in 65 (54%), f air in 31 (25%), no response in 7 (6%), and worse in 1 (1%), The best respo nses were noted for soft-tissue signs, extraocular muscle involvement, and sight loss, while a limited response was noted for proptosis, Multivariate analysis revealed that the use of high-dose corticosteroid or pulsed cortic osteroids, female gender, and a shorter duration of ophthalmopathy before r adiotherapy were significantly correlated with favorable outcomes. No long- term complications related to radiotherapy were observed. Conclusion: Orbital irradiation combined with high-dose or pulsed corticost eroids is an effective treatment for moderate to severe GO, especially in c ases with major manifestations of soft-tissue signs, extraocular muscle imp airment, or sight loss. (C) 2000 Elsevier Science Inc.